Trials / Completed
CompletedNCT00550212
Study Evaluating Oral Administrations of HKI-272 in Healthy Male Subjects
An Open-Label, Single-Dose Study of the Mass Balance and Metabolic Disposition of Orally Administered [14C]-Labeled HKI-272 in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Puma Biotechnology, Inc. · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the mass balance and metabolic distribution of C14-labeled HKI-272 in healthy male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | neratinib | HKI-272, Single-dose capsule and solution |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2008-04-01
- Completion
- 2008-04-01
- First posted
- 2007-10-29
- Last updated
- 2012-05-14
Source: ClinicalTrials.gov record NCT00550212. Inclusion in this directory is not an endorsement.